Abstract
A phase II trial of etoposide (100 mg/m2) on days 4, 5, 6, doxorubicin (Adriamycin, 20 mg/m2) on days 1, 7, and cisplatin (30 mg/m2) on days 2, 8 (EAP) was carried out in order to reduce toxicity associated with a full-dose EAP regimen for advanced and/or metastatic gastric adenocarcinoma. Out of 21 evaluable patients, 2 (10%) had a complete response (CR), 7 (33%) had a partial response (PR), 4 (20%) showed no change and 8 progressed (38%). The mean duration of response (CR+PR) was 8.4+ months. Survival of the whole group was 7.5+ months. Treatment was quite well tolerated by most patients on an outpatient basis. Grade 3 vomiting and leukopenia were seen in 30% and 35% of cases respectively. One patient had grade 3 esophagitis, and 1 patient was hospitalized for severe grade 4 febrile leukopenia. Although the EAP regimen cannot be considered a standard therapy for gastric cancer, the EAP schedule employed in this study seems to be better tolerated than those reported by other authors, and can sefely be given on an outpatient basis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gastrointestinal Tumor Study Group (1984) Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 53:13–17
Haim N, Cohen Y, Honigman J, Robinson E (1982) Treatment of advanced gastric carcinoma with 5-fluorouracil, Adriamycin, and mitomycin C (FAM). Cancer Chemother Pharmacol 8:277–280
Katz A, Gansl R, Simon S, et al. (1989) Phase II trial of VP16 (V), Adriamycin (A), and cisplatinum (C) in patients (pts) with advanced gastric cancer (ACG). Proc Am Soc Clin Oncol 8:98
Kelsen D, Atiq OT, Saltz L, et al (1992) FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10:541–548
Klein HO, Dias Wickramanayake P, Farrokh GH, et al (1986) 5-Fluorouracil (FU), Adriamycin (ADM) and methotrexate (MTX)-a combination protocol (FAMTX) for treatment of metastasized stomach cancer. Proc Am Soc Clin Oncol 5:84
Le Chevalier T, Smith FP, Harter WK, Schein PS (1985) Chemotherapy and combined modality therapy for locally advanced and metastatic gastric carcinoma. J Clin Oncol 12:46–53
Lerner A, Gonin R, Steele GD, Mayer RJ (1992) Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol 10:536–540
McDonald JS, Gohman JJ (1988) Chemotherapy of advanced gastric cancer: present status, future prospects. Semin Oncol 15:42–49
McDonald JS, Schein PS, Wooley PV, et al (1990) 5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93:533–536
O'Connell MJ (1992) Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric cancer: an old lesson rivisited. J Clin Oncol 10:515–516
Preusser P, Wilke H, Achterrath W, et al (1989) Phase II study with the combination of etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310–1317
Schabel FM, Trader MW, Laster WR, et al (1979)cis-Dichlorodiammine-platinum (II): combination chemotherapy and crossresistance studies with tumor of mice. Cancer Treat Rep 63:1459–1473
Sparano JA, Schwartz EL, Salva KM, et al (1990) Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer. Am J Clin Oncol 13:374–378
Taguchi T (1989) Combination chemotherapy with etoposide (E), adriamycin (A), and cisplatin (P) (EAP) for advanced gastric cancer. Proc Am Soc Clin Oncol 8:108
Taal BG, Bokkel Huinink WW ten, Franklin H, et al (1990) EAP in advanced gastric cancer. J Clin Oncol 8:939–940
WHO/UICC (1979) Handbook for reporting results of cancer treatment. WHO Offset Publ 48
Wilke H, Preusser P, Fink U, et al (1989) Preoperative chemotherapy in locally advanced and non resectable gastric cancer. J Clin Oncol 7:1318–1326
Wils JA (1987) Current status of chemotherapy for advanced gastric cancer. Anticancer Res 7:755–760
Wils J, Bleiberg H, Blijham G, et al (1986) An EORTC gastrointestinal group evaluation of the combination of sequential methotrexate (MTX), and 5-fluorouracil (F), combined with adriamycin (A) (FAMTX) in advanced measurable gastric cancer. J Clin Oncol 4:1799–1803
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gebbia, V., Valenza, R., Testa, A. et al. Etoposide, doxorubicin (Adriamycin) and cisplatin regimen in advanced gastric adenocarcinoma: experience with a lower dose schedule. J Cancer Res Clin Oncol 120, 550–552 (1994). https://doi.org/10.1007/BF01221033
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01221033